⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
Transposon Therapeutics, Inc.
What this score means
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. Transposon Therapeutics, Inc. just got measured.
4/10 means Transposon Therapeutics, Inc. is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
About Transposon Therapeutics, Inc.
Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Details
AI Visibility Breakdown
1
Structured Data
4
Content Structure
5
Entity Clarity
2
E-E-A-T Signals
7
Technical AEO
2
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Tech Shoppers Do More Research Than Anyone. Are You There When They're Looking?
Tech buyers are the most research-intensive shoppers on the internet.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Transposon Therapeutics, Inc..
Source & Attribution
Scored by Engagemii on June 24, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/transposonrx
Cite this score: Engagemii (2026). "AEO Score for Transposon Therapeutics, Inc.." Retrieved from https://engagemii.com/aeo/brands/transposonrx
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform